Saint Paul Les Dax

Researchers are evaluating four different isotonic and hypertonic seawater-based nasal sprays in real-life settings for their effectiveness, safety, usage, tolerance, and user satisfaction. The study focuses on infants, children, adults, and pregnant or breastfeeding women who have acute or chronic sinonasal conditions such as upper respiratory tract infections, allergic rhinitis, chronic rhinosinusitis, bronchiolitis, COVID-19, and post-surgery nasal issues. The investigation aims to understand how these devices perform when used as intended across various patient groups. Participants will use one of four CE-marked nasal spray devices according to their specific indications and target populations. The sprays include Respimer Hygiene-Prevention for babies, kids, and adults, Respimer Decongestion for babies from two months old and older, and Phytosun arms Hypertonic nasal wash for children six years and older and adults. Usage instructions vary by product, ranging from 1 to 6 sprays per nostril daily, with different frequencies for treatment and prevention purposes. The study period covers up to three months to assess both short-term and longer-term effects. During the study, participants or their parents will complete online questionnaires and follow healthcare providers advice on nasal wash techniques. Researchers will monitor nasal symptom changes, including intensity and frequency, improvement in nasal breathing, quality of life, and satisfaction with the sprays. Effectiveness will be evaluated from day 0 to day 5 for acute conditions and up to day 14 for chronic issues, extending to three months for seasonal symptom management. Safety, tolerance, and usage patterns will also be recorded throughout the study.

Hemiparesis, a common motor disorder following a stroke, often results in patients not regaining functional use of their affected upper limb. This research aims to evaluate whether using mirror therapy through an Intensive Visual Simulation IVS device can improve motor function and abilities of the distal upper limb in patients with moderate to severe hemiparesis during the subacute phase, between 4 and 10 weeks after stroke. The study compares this approach to conventional rehabilitation care in a randomized controlled trial. Participants will receive treatment over 6 weeks with at least 4 sessions per week. One group will undergo conventional occupational therapy involving passive stretching, assisted active movements, and gripping tasks adapted to their abilities. The other group will receive a combination of 45 minutes of conventional therapy and 15 minutes using the IVS3 device, which projects the mirrored image of the unaffected limb to create the illusion of movement in the affected arm. The IVS3 device is designed to make mirror therapy immersive and ergonomic, supporting intensive movement repetition. During the 18-week participation, patients will be assessed at the start, end of the 6-week program, and 12 weeks later. Evaluations include motor performance using the Fugl-Meyer wristhand sub-score, motor capacity scales, spasticity measures, and stroke impact questionnaires. The study monitors patient comfort, adherence to therapy, and any potential discomfort in early device use. The research aims to understand if substituting part of routine care with IVS improves distal motor control compared to standard rehabilitation.